Stephen D Rubin
Overview
Explore the profile of Stephen D Rubin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
3404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, et al.
Haematologica
. 2018 Aug;
104(1):113-119.
PMID: 30076173
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with acute...
2.
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al.
N Engl J Med
. 2014 Nov;
372(1):30-9.
PMID: 25399551
Background: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK...
3.
Sternberg C, Hawkins R, Wagstaff J, Salman P, Mardiak J, Barrios C, et al.
Eur J Cancer
. 2013 Jan;
49(6):1287-96.
PMID: 23321547
Background: In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC)....
4.
Cristofanilli M, Johnston S, Manikhas A, Gomez H, Gladkov O, Shao Z, et al.
Breast Cancer Res Treat
. 2012 Dec;
137(2):471-82.
PMID: 23239151
This multi-center Phase II study evaluated lapatinib, pazopanib, and the combination in patients with relapsed HER2+ inflammatory breast cancer. In Cohort 1, 76 patients were randomized 1:1 to receive lapatinib...
5.
Taskar K, Rudraraju V, Mittapalli R, Samala R, Thorsheim H, Lockman J, et al.
Pharm Res
. 2011 Oct;
29(3):770-81.
PMID: 22011930
Purpose: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+...
6.
Lin N, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, et al.
J Neurooncol
. 2011 Jun;
105(3):613-20.
PMID: 21706359
Approximately one-third of patients with advanced, HER2-positive breast cancer develop brain metastases. A significant proportion of women experience central nervous system (CNS) progression after standard radiation therapy. The optimal treatment...
7.
Lin N, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler H, et al.
Clin Cancer Res
. 2009 Feb;
15(4):1452-9.
PMID: 19228746
Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited...
8.
Molina J, Kaufmann S, Reid J, Rubin S, Galvez-Peralta M, Friedman R, et al.
Clin Cancer Res
. 2008 Dec;
14(23):7900-8.
PMID: 19047120
Purpose: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members....
9.
Gril B, Palmieri D, Bronder J, Herring J, Vega-Valle E, Feigenbaum L, et al.
J Natl Cancer Inst
. 2008 Jul;
100(15):1092-103.
PMID: 18664652
Background: The brain is increasingly being recognized as a sanctuary site for metastatic tumor cells in women with HER2-overexpressing breast cancer who receive trastuzumab therapy. There are no approved or...
10.
Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T, et al.
N Engl J Med
. 2006 Dec;
355(26):2733-43.
PMID: 17192538
Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination...